Bayer Soars After $10.5 Billion Settlement On Current And Future Roundup Cancer Lawsuits
What Happened
Bayer, the German chemical giant, has announced a $10.5 billion settlement to resolve current and future cancer lawsuits over its Roundup weedkiller. This settlement is a crucial step for the company to address the legal risks associated with the use of Roundup, which has been linked to the development of non-Hodgkin's lymphoma in some users.
The settlement comprises:
- ●$7.5 billion class-action settlement through cases filed in state court in Missouri to resolve Roundup suits that have already been filed and potential claims that could be filed over a 20-year period.
- ●$3 billion in settlements of existing U.S. cases where former Roundup users have blamed the herbicide for causing their non-Hodgkin's lymphoma.
- ●Bayer has already paid around $10 billion to settle most of the Roundup lawsuits that were pending as of 2020, but this new settlement aims to cover future cases as well.
Why It Matters
The $10.5 billion settlement is a significant development for Bayer, as it aims to resolve the legal risks associated with Roundup, which has been a major source of concern for the company since its acquisition of Monsanto in 2018.
"We are entering into the settlement because it is an important addition to the case before the Supreme Court, thereby minimising the legal risks as comprehensively as possible," said Bayer CEO Bill Anderson.
The settlement comes as Bayer is also pursuing a Supreme Court case to have a ruling that found Roundup caused cancer overturned. The combination of the class-action settlement and the Supreme Court case is seen as a comprehensive approach to addressing the legal risks.
The settlement is likely to have a positive impact on Bayer's stock price, as it provides clarity and certainty around the company's Roundup-related liabilities. The stock surged on the news of the settlement, indicating that investors see it as a positive development for the company.
However, the settlement also highlights the significant financial burden that Bayer has faced due to the Roundup lawsuits. The company has now paid over $20 billion to resolve these cases, which has had a significant impact on its financial performance and may continue to do so in the future.
What to Watch
As Bayer moves forward with the settlement, there are several key things to watch:
- ●The progress of the Supreme Court case, as the outcome could have further implications for Bayer's legal exposure.
- ●The number of new lawsuits that continue to be filed against Bayer, as the settlement is designed to cover claims for the next 20 years.
- ●The impact of the settlement on Bayer's financial performance, including any potential write-downs or charges related to the settlement.
- ●The response from Roundup users and advocacy groups, as the settlement may not be seen as a complete resolution of the issue by all stakeholders.
This insight was generated from news published by Bloomberg. For the full original article, visit the source.